Please login to the form below

Not currently logged in
Email:
Password:

sebelipase alfa

This page shows the latest sebelipase alfa news and features for those working in and with pharma, biotech and healthcare.

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion adds to pipeline rebuild with $855m Wilson buy

A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still ... However, its 2015 takeover of Synageva for $8.4bn has been less

Latest news

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    New draft guidance from NICE means that the wider population of infants with HPP - not just those with the most severe form - will be eligible for treatment with Strensiq (asfotase alfa), ... NICE also turned down Alexion's other new enzyme replacement

  • NICE blocks second Alexion rare disease drug in a week NICE blocks second Alexion rare disease drug in a week

    A final ruling from the UK's cost-effectiveness watchdog has concluded that the high cost of Kanuma (sebelipase alfa) - at almost £500, 000 per patient per year - cannot be justified ... Throughout this extremely complicated evaluation we have given the

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    Janssen. MCL, CLL, WM. sebelipase alfa. Kanuma. Alexio. Lysosomal acid lipase deficiency (LAL-D). ... asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    These were Kanuma (sebelipase alfa), the first-ever treatment for the rare, inherited disorder lysosomal acid lipase deficiency - and Strensiq (asfotase alfa), the first enzyme replacement therapy for patients with infantile- ... EU. sebelipase alfa.

  • NICE wants more data on Alexion's orphan drug Kanuma NICE wants more data on Alexion's orphan drug Kanuma

    data on whether [sebelipase alfa] completely reversed LAL-D over the long term and prevented complications of the condition". ... Even based on more optimistic assumptions of long-term treatment effect, the cost of sebelipase alfa would be very high,"

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    This agreement brings access to Kanuma (sebelipase alfa) which is in registration for the treatment of lysosomal acid lipase (LAL) deficiency. ... Corporate acquisition. Rare diseases portfolio including Kanuma (sebelipase alpha) for LAL deficiency.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics